Immix Biopharma (NASDAQ:IMMX) Shares Up 7.7% – What’s Next?

Immix Biopharma, Inc. (NASDAQ:IMMX)’s stock price rose 7.7% during mid-day trading on Tuesday . The company traded as high as $10.74 and last traded at $10.6790. Approximately 492,627 shares traded hands during mid-day trading, a decline of 40% from the average daily volume of 827,066 shares. The stock had previously closed at $9.92.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Mizuho increased their price target on Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a research report on Monday, March 30th. Citizens Jmp reissued a “market outperform” rating and issued a $23.00 price objective on shares of Immix Biopharma in a research note on Friday, March 27th. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research note on Sunday, March 15th. Morgan Stanley began coverage on Immix Biopharma in a report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Tuesday, April 21st. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Immix Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Immix Biopharma Stock Performance

The firm’s 50-day moving average is $9.39 and its two-hundred day moving average is $6.74. The stock has a market cap of $572.12 million, a P/E ratio of -11.57 and a beta of 0.12.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. As a group, research analysts forecast that Immix Biopharma, Inc. will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. LGT Fund Management Co Ltd. boosted its stake in shares of Immix Biopharma by 233.3% in the 1st quarter. LGT Fund Management Co Ltd. now owns 416,594 shares of the company’s stock valued at $3,795,000 after purchasing an additional 291,594 shares during the last quarter. Private Advisor Group LLC grew its holdings in Immix Biopharma by 9.5% during the 1st quarter. Private Advisor Group LLC now owns 34,725 shares of the company’s stock worth $316,000 after acquiring an additional 3,000 shares during the period. Kera Capital Partners Inc. bought a new stake in shares of Immix Biopharma during the 4th quarter valued at $68,000. Virtu Financial LLC bought a new position in shares of Immix Biopharma in the 4th quarter worth $386,000. Finally, KVP Capital Advisors LP acquired a new stake in shares of Immix Biopharma during the fourth quarter worth $1,205,000. 11.26% of the stock is currently owned by institutional investors and hedge funds.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.